RPTX
Repare·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
RPTX Profile
Repare Therapeutics Inc.
A leading clinical-stage precision oncology company that develops drugs for patients that target specific vulnerabilities of tumor cells
Biological Technology
09/06/2016
06/19/2020
NASDAQ Stock Exchange
129
12-31
Common stock
7171 Frederick-Banting, Building 2, Suite 270, St-Laurent, Québec, Canada H4S 1Z9
--
Repare Therapeutics Inc. was incorporated on September 6, 2016 under the Canadian Business Corporations Act. The Company is a leading precision oncology company with proprietary synthetic-killing methods for the discovery and development of novel therapies. Synthetic lethality, or SL, represents a clinically proven approach to drug development. The company uses its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies for genomic instability, including DNA damage repair. SL occurs when the deletion of either of the two genes is tolerated in the cell, but the simultaneous deletion of both genes leads to cell death. SL occurs when a deficiency of either of two genes in a cell is tolerated, but a simultaneous deficiency of both genes can lead to cell death. The company is using its SNIPRx platform to develop its pipeline of SL product candidates, including its product candidate RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
